What one share of Immunocore Holdings holds
We are a commercial stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases.
Immunocore Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.33 |
|---|---|
| Profit | −$0.35 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$0.80 |
| Cash and investments | $17.10 |
| Book value | $8.15 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.86 | −$4.24 | $0.03 | −$3.40 | — | $5.33 |
| 2022 | $3.81 | −$1.15 | $0.05 | −$1.12 | $0.00 | $7.05 |
| 2023 | $5.10 | −$1.13 | $0.11 | −$0.05 | $0.00 | $7.42 |
| 2024 | $6.21 | −$1.02 | $0.10 | $0.42 | $0.00 | $7.21 |
| 2025 | $7.95 | −$0.71 | $0.09 | −$0.30 | $0.00 | $7.52 |
Common questions about Immunocore Holdings
How much does one share of Immunocore Holdings earn?
Over the last 12 months, Immunocore Holdings lost $0.35 for each share on $8.33 of sales.
Does Immunocore Holdings pay a dividend?
Immunocore Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immunocore Holdings’s book value per share?
Immunocore Holdings’s book value is $8.15 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immunocore Holdings have?
Each share of Immunocore Holdings has $17.10 of cash and investments, as of June 30, 2026.
What is Immunocore Holdings’s free cash flow per share?
−$0.80 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immunocore Holdings bought back shares?
Immunocore Holdings’s share count rose about 18% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.